Stephen V Liu, Chief, Division of Hematology and Oncology at Georgetown Lombardi Comprehensive Cancer Center, Director of Thoracic Oncology and Developmental Therapeutics, shared a post on X:
“FLAURA2 press release: addition of chemotherapy to 1L osimertinib in EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update!”
Read Full Press Release.
Read More about NSCLC on OncoDaily.
